IDegAsp (insulin degludec + insulin aspart) for the management of type 2 diabetes: current status
Author:
Funder
Novo Nordisk
Publisher
Informa UK Limited
Subject
Endocrinology, Diabetes and Metabolism
Link
http://www.tandfonline.com/doi/pdf/10.1586/17446651.2016.1145541
Reference47 articles.
1. Effects of Glycemic Control on Diabetes Complications and on the Prevention of Diabetes
2. Overview of Newer Agents: Where Treatment Is Going
3. Diabetic Nephropathy: Diagnosis, Prevention, and Treatment
4. UKPDS 50: Risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis
5. Diabetic Neuropathies
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Initiating or switching to IDegAsp in a real-world South African population with type 2 diabetes – a cohort analysis from the ARISE study;Journal of Endocrinology, Metabolism and Diabetes of South Africa;2023-05-19
2. Comparative efficiency and safety of insulin degludec/aspart with insulin glargine in type 2 diabetes: a meta-analysis of randomized controlled trials;Endocrine Journal;2022
3. Efficacy and Safety of Insulin Degludec/Insulin Aspart Compared with a Conventional Premixed Insulin or Basal Insulin: A Meta-Analysis;Metabolites;2021-09-18
4. Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes;Diabetes, Obesity and Metabolism;2016-09-26
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3